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MUC5B rs35705950 (G/T) is strongly associated with idiopathic pulmonary fibrosis (IPF) and also contributes 
to the risk of interstitial lung disease (ILD) in rheumatoid arthritis (RA-ILD) and chronic hypersensitivity 
pneumonitis (CHP). Due to this, we evaluated the implication of MUC5B rs35705950 in antisynthetase 
syndrome (ASSD), a pathology characterised by a high ILD incidence. 160 patients with ASSD (142 with ILD 
associated with ASSD [ASSD-ILD+]), 232 with ILD unrelated to ASSD (comprising 161 IPF, 27 RA-ILD and 
44 CHP) and 534 healthy controls were genotyped. MUC5B rs35705950 frequency did not significantly differ 
between ASSD-ILD+ patients and healthy controls nor when ASSD patients were stratified according to 
the presence/absence of anti Jo-1 antibodies or ILD. No significant differences in MUC5B rs35705950 were 
also observed in ASSD-ILD+ patients with a usual interstitial pneumonia (UIP) pattern when compared to 
those with a non-UIP pattern. However, a statistically significant decrease of MUC5B rs35705950 GT, TT 
and T frequencies in ASSD-ILD+ patients compared to patients with ILD unrelated to ASSD was observed. 
In summary, our study does not support a role of MUC5B rs35705950 in ASSD. It also indicates that there 
are genetic differences between ILD associated with and that unrelated to ASSD.
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Mucins are components of mucus secretions with a crucial implication in the host defence against bacterial and 
fungal infections1. Mucin 5B is a gel-forming mucin and a major constituent of mucus in the respiratory tract2 
that is encoded by MUC5B3. A common gain-of-function variant located in the promoter of this gene, MUC5B 
rs35705950, is described as the strongest genetic risk factor for the development of idiopathic pulmonary fibro-
sis (IPF)4, the most common and pernicious form of interstitial lung disease (ILD)5. A recent study performed 
by Juge et al. has revealed that MUC5B rs35705950 also significantly contributes to the risk of ILD amongst 
patients with rheumatoid arthritis (RA-ILD)6. In addition, MUC5B rs35705950 has been previously associated 
with chronic hypersensitivity pneumonitis (CHP), a relevant finding reported by Ley et al.7.
Antisynthetase syndrome (ASSD) is a connective tissue disease characterized by the typical clinical triad of 
arthritis, myositis and ILD8–13. Amongst these clinical features, ILD has been identified as the most frequent14 
and severe15 manifestation of ASSD, with an incidence of approximately 80–90%16,17. The type and severity of ILD 
defines the long-term outcome of ASSD10, being the major determinant of morbidity and mortality in patients 
affected with this condition10,17–22. The pathophysiology of ASSD is not entirely understood, although some pieces 
of evidence support the hypothesis that both genetic and environmental factors may play a relevant role23.
Taking all these considerations into account, we aimed to determine whether the MUC5B rs35705950 pro-
moter polymorphism, associated with IPF4, RA-ILD6 and CH7, was also implicated in the pathogenesis of ASSD. 
For this purpose, we took advantage of data from one of the largest cohorts of patients with ASSD.
Patients and Methods
Patients and study protocol. A total of 160 unrelated Spanish patients of European ancestry (self-re-
ported) diagnosed with ASSD were enrolled in this study. Centres involved in the recruitment of these patients 
included Hospital Universitario Marqués de Valdecilla (Santander), Hospital Universitario San Cecilio (Granada), 
Hospital Clínico Universitario de Santiago (Santiago de Compostela), Hospital Universitario Araba (Vitoria), 
Hospital Clínico de Barcelona, Hospital Universitario de Bellvitge and Hospital Universitario Valle de Hebrón 
(Barcelona), and Hospital General Universitario Gregorio Marañón, Hospital Universitario Fundación Jiménez 
Díaz, Hospital Universitario La Paz and Hospital Universitario de la Princesa (Madrid). Patients were recruited if 
they had an antisynthetase antibody testing positive in at least two determinations along with one or more find-
ings of the typical clinical triad (arthritis, myositis and/or ILD). Briefly, arthritis occurrence and its presentation 
pattern were clinically assessed by the referent physician; myositis was defined in case of muscle enzyme elevation 
(creatinine phosphokinase and/or aldolase) and the presence of typical electromyography alterations and/or com-
patible muscle biopsy findings and/or compatible muscle magnetic resonance; ILD was defined instrumentally by 
a restrictive pulmonary function test pattern [forced vital capacity (FVC) ≤ 80%, forced expiratory volume in one 
second (FEV1)/FVC ≥ 70%, decreased/normal FEV1, and/or diffusing capacity of the lung for carbon monoxide 
(DLCO) reduction >20%] and/or by the identification of alveolitis/fibrosis signs at high-resolution computed 
tomography of the lungs8,9,12,24,25. According to these criteria, 142 (88.8%) patients developed ILD associated with 
ASSD (ASSD-ILD+). Among them, 70% showed a non-specific interstitial pneumonia (NSIP) pattern in the 
high-resolution computed tomography (HRCT) images of the chest, while 19% of the patients showed a usual 
interstitial pneumonia (UIP) pattern. The remaining 11% of the ASSD-ILD+ patients presented other patterns. 
The occurrence of accompanying features, including fever, Raynaud´s phenomenon and mechanic’s hands, were 
also assessed as previously described11,18. Fever was considered in case of a body temperature ≥38 °C for more 
than 10 days without evidence of any other reason. Raynaud’s phenomenon was determined as the occurrence of 
a transient finger ischemia after cold exposure. Mechanic’s hands were defined as the occurrence of a thickened, 
hyperkeratotic, and fissured aspect of the radial sides of the fingers of the hands, in absence of other causes12,19. A 
detailed description of the main demographic and clinical information of the patients with ASSD enrolled in this 
study is displayed in Table 1.
In addition, a set of 232 ethnically matched (self-reported) patients diagnosed with ILD unrelated to ASSD was 
also included in this work. Centres involved in the recruitment of these patients included Hospital Universitario 
Marqués de Valdecilla (Santander), and Hospital Universitario Puerta de Hierro and Hospital Universitario 12 de 
Octubre (Madrid). Amongst these patients, 161 (69.4%) exhibited IPF, according to the classification criteria for 
the disease26, whereas 27 (11.6%) experienced RA-ILD and 44 (19.0%) exhibited CHP.
Moreover, a total of 534 ethnically (self-reported) matched unaffected control subjects, without history of 
any autoimmune or pulmonary disease, constituted by blood donors from Hospital Universitario Marqués de 
Valdecilla (Santander) and National DNA Bank Repository (Salamanca), was also enrolled in the study.
All patients and healthy controls signed an informed written consent before being included in the study, 
according to the declaration of Helsinki. The procedures followed were in accordance with the ethical stand-
ards of the approved guidelines and regulations, according to the Declaration of Helsinki. All experimental 
protocols were approved by the Ethics Committees of clinical research of Cantabria for Hospital Universitario 
Marqués de Valdecilla in Santander, of Andalucía for Hospital Universitario San Cecilio in Granada, of Galicia 
for Hospital Clínico Universitario de Santiago in Santiago de Compostela, of País Vasco for Hospital Universitario 
Araba in Vitoria, of Cataluña for Hospital Clínico de Barcelona, Hospital Universitario de Bellvitge and Hospital 
Universitario Valle de Hebrón in Barcelona, and of Madrid for Hospital General Universitario Gregorio Marañón, 
Hospital Universitario Fundación Jiménez Díaz, Hospital Universitario La Paz, Hospital Universitario de la 
Princesa, Hospital Universitario Puerta de Hierro and Hospital Universitario 12 de Octubre in Madrid.
Single nucleotide polymorphism selection and genotyping. The common gain-of-function genetic 
variant MUC5B rs35705950 (G/T), described as the strongest risk factor for IPF4 that also contributes to the risk 
of RA-ILD6, was selected in this study.
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Genomic deoxyribonucleic acid from patients with ASSD, patients with ILD unrelated to ASSD and healthy 
controls was extracted from peripheral blood using standard procedures. All patients and healthy controls were 
genotyped for the MUC5B polymorphism mentioned above using a predesigned TaqMan 5′ single-nucleotide poly-
morphism genotyping assay (C_1582254_20) in a QuantStudioTM 7 Flex Real-Time polymerase chain reaction sys-
tem, according to the conditions recommended by the manufacturer (Applied Biosystems, Foster City, CA, USA).
Negative controls and duplicate samples were included to check the accuracy of the genotyping.
Statistical analysis. Genotype data were checked for deviation from Hardy-Weinberg equilibrium (HWE) 
by chi-square test.
Both genotype and allele frequencies of MUC5B rs35705950 were calculated and compared between 
ASSD-ILD+ patients and healthy controls, patients with ASSD stratified according to specific clinical features 
of the disease (presence/absence of anti Jo-1 antibodies or ILD), ASSD-ILD+ patients stratified according to the 
presence of an UIP and non-UIP HRCT pattern, as well as between ASSD-ILD+ patients and those with ILD 
unrelated to ASSD.
To test for association, 3 × 2 and 2 × 2 contingency tables as well as chi-square test and/or Fisher´s exact test, 
when appropriate, were used. Strength of associations were estimated using odds ratios and 95% confidence inter-
vals. P-values lower than 0.05 were considered as statistically significant.
All analyses were performed with STATA statistical software 12/SE (Stata Corp., College Station, TX, USA).
Results
The genotyping success rate was greater than 99%.
No evidence of departure from HWE was observed in healthy controls at the 5% significance level. Genotype 
and allele frequencies of MUC5B rs35705950 in healthy controls were similar to those reported for populations of 
European origin in the 1000 Genomes Project (http://www.internationalgenome.org/).
Differences in genotype and allele frequencies of MUC5B rs35705950 between ASSD-ILD+ 
patients and healthy controls. Firstly, we compared genotype and allele frequencies of MUC5B 
rs35705950 between ASSD-ILD+ patients and healthy controls.
As shown in Table 2, no statistically significant differences in the genotype frequencies of MUC5B rs35705950 
were disclosed when ASSD-ILD+ patients were compared to healthy controls. Likewise, allele frequencies of 
MUC5B rs35705950 did not significantly differ between ASSD-ILD+ patients and healthy controls (Table 2).
Differences in genotype and allele frequencies of MUC5B rs35705950 between patients with 
ASSD stratified according to specific clinical features of the disease. In a further step, we analysed 
potential differences in the genotype and allele frequencies of MUC5B rs35705950 between patients with ASSD 
stratified according to the presence/absence of anti Jo-1 antibodies or ILD.
No genotype or allele differences in MUC5B rs35705950 were observed when patients with ASSD were strat-
ified according to the presence/absence of anti Jo-1 antibodies (Table 3). It was also the case when patients with 
ASSD who developed ILD were compared to those who did not exhibit this pulmonary complication (Table 3).
Differences in genotype and allele frequencies of MUC5B rs35705950 between ASSD-ILD+ 
patients stratified according to the presence of an UIP and non-UIP HRCT pattern”. Moreover, 
we also evaluated potential differences in the genotype and allele frequencies of MUC5B rs35705950 between 
ASSD-ILD+ patients stratified according to the presence of an UIP and non-UIP HRCT pattern.
No genotype or allele differences in MUC5B rs35705950 were observed in ASSD-ILD+ patients with an UIP 
pattern when compared to those with a non-UIP pattern (Table 4).
Differences in genotype and allele frequencies of MUC5Brs35705950 between ASSD-ILD+ 
patients and patients with ILD unrelated to ASSD. We also examined whether genotype or allele fre-
quencies of MUC5B rs35705950 differed between patients with ASSD-ILD+ and those with ILD unrelated to ASSD.
[% (n/N)]
Median age in years at disease onset [IQR] 48.0 [37.0–58.7]
Median follow-up in months [IQR] 81.5 [45.0–170.5]
Percentage of females 69.7
Antisynthetase antibody 100.0 (160/160)
Anti Jo-1 positive 65.0 (104/160)
Arthritis 62.5 (100/160)
Myositis 69.4 (111/160)
ILD 88.8 (142/160)
Fever 34.4 (53/154)
Raynaud’s phenomenon 37.7 (58/154)
Mechanic’s hands 56.5 (87/154)
Table 1. Main demographic and clinical information of the 160 patients diagnosed with ASSD included in this 
study. ASSD: antisynthetase syndrome; IQR: interquartile range; ILD: interstitial lung disease.
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Interestingly, we disclosed a statistically significant decrease of MUC5B rs35705950 GT, TT and T frequencies 
in patients with ASSD-ILD + compared to the whole cohort of patients with ILD unrelated to ASSD (GT: 19.7% 
versus 53.4%, p < 0.0001; TT: 0.7% versus 9.1%, p < 0.0001; T: 10.6% versus 35.8%, p < 0.0001) (Supplementary 
Table 1). This significant decrease was also observed when patients with ASSD-ILD + were compared to 
those with IPF (GT: 19.7% versus 58.8%, p < 0.0001; TT: 0.7% versus 6.9%, p < 0.0001; T: 10.6% versus 36.0%, 
p < 0.0001), RA-ILD (GT: 19.7% versus 40.7%, p = 0.006; TT: 0.7% versus 11.1%, p = 0.0001; T: 10.6% versus 
31.5% p < 0.0001) and CHP (GT: 19.7% versus 43.2%, p = 0.0001; TT: 0.7% versus 15.9%, p < 0.0001; T: 10.6% 
versus 37.5% p < 0.0001 (Supplementary Table 1).
Discussion
Pathogenic similarities amongst diseases linked to ILD have been identified5,27. In this regard, an excess of muta-
tions in genes previously associated with IPF has recently been detected in RA-ILD28, raising the question of 
whether a common genetic background underlies ILD related entities.
Taking into account these considerations, we aimed to evaluate for the first time the potential implication of 
MUC5B rs35705950 polymorphism, associated with IPF4, RA-ILD6 and CHP7, in the pathogenesis of ASSD, a dis-
ease characterised by a high ILD incidence. Our results showed no influence of this genetic variant in the suscep-
tibility to ASSD. Furthermore, no specific association of MUC5B rs35705950 with clinical features of ASSD was 
ASSD-ILD + % (n) Healthy controls % (n) p OR [95% CI]
MUC5B rs35705950
Genotypes
GG 79.6 (113) 77.2 (412) — ref.
GT 19.7 (28) 21.2 (113) 0.67 0.90 [0.55–1.46]
TT 0.7 (1) 1.7 (9) 0.38 0.41 [0.01–2.98]
Alleles
G 89.4 (254) 87.7 (937) — ref.
T 10.6 (30) 12.3 (131) 0.43 0.84 [0.54–1.30]
Table 2. Genotype and allele frequencies of MUC5B rs35705950 in ASSD-ILD + patients and healthy controls. 
ASSD: antisynthetase syndrome; ILD: interstitial lung disease; OR: odds ratio; CI: confidence interval.
ASSD
p OR [95% CI]
ASSD
p OR [95% CI]anti Jo-1 + % (n) anti Jo-1- % (n) ILD + % (n) ILD- % (n)
MUC5B rs35705950
Genotypes
GG 83.7 (87) 73.2 (41) — Ref. 79.6 (113) 83.3 (15) — ref.
GT 15.4 (16) 25.0 (14) 0.13 0.54 [0.22–1.32] 19.7 (28) 11.1 (2) 0.42 1.85 [0.39–17.63]
TT 1.0 (1) 1.8 (1) 0.59 0.47 [0.006–37.88] 0.7 (1) 5.6 (1) 0.10 0.13 [0.002–11.11]
Alleles
G 91.3 (190) 85.7 (96) — Ref. 89.4 (254) 88.9 (32) — ref.
T 8.7 (18) 14.3 (16) 0.12 0.57 [0.26–1.25] 10.6 (30) 11.1 (4) 0.92 0.94 [0.30–3.93]
Table 3. Genotype and allele frequencies of MUC5B rs35705950 in patients with ASSD stratified according 
to the presence/absence of anti-Jo-1 antibodies or ILD. ASSD: antisynthetase syndrome; ILD: interstitial lung 
disease; OR: odds ratio; CI: confidence interval.
UIP % (n) Non-UIP % (n) p OR [95% CI]
MUC5B rs35705950
Genotypes
GG 70.4 (19) 81.1 (86) — ref.
GT 29.6 (8) 17.9 (19) 0.19 1.91 [0.62–5.41]
TT 0.0 (0) 1.0 (1) — —
Alleles
G 85.2 (46) 90.1 (191) — ref.
T 14.8 (8) 9.9 (21) 0.30 1.58 [0.57–4.01]
Table 4. Genotype and allele frequencies of MUC5B rs35705950 in ASSD-ILD + patients stratified according 
to the presence of an UIP and non-UIP pattern. ASSD: antisynthetase syndrome; ILD: interstitial lung disease; 
UIP: usual interstitial pneumonia; OR: odds ratio; CI: confidence interval.
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observed in our study, indicating that this polymorphism does not represent a risk factor for the severity of the 
disease, and especially for ASSD-ILD+ patients. Additionally, no significant differences in MUC5B rs35705950 
were also observed in ASSD-ILD+ patients with an UIP pattern when compared to those with a non-UIP pattern. 
Interestingly, statistically significant differences in MUC5B rs35705950 frequencies between ASSD-ILD+ patients 
and those with ILD unrelated to ASSD (particularly IPF, RA-ILD and CHP) were found. This data suggests a dif-
ferent genetic predisposition between these conditions.
In keeping with our results in ASSD and unlike RA-ILD, no association of MUC5B rs35705950 with ILD in 
the setting of other connective tissue diseases was found. With respect to this, no influence of this genetic variant 
on myositis-ILD was disclosed whereas genetic differences regarding MUC5B rs35705950 between myositis-ILD 
and idiopathic ILD were also reported29. Likewise, lack of association between this genetic variant and ILD in 
the context of sarcoidosis30 and systemic sclerosis30,31 was described while differences in MUC5B rs35705950 
frequencies were found when patients with sarcoidosis-ILD30 and those with systemic sclerosis-ILD30,31 were 
compared to patients with IPF.
Despite parallelisms amongst the different phenotypes of ILD, many clinical and radiological differences have 
been established5,27,32. In this regard, a NSIP pattern is more commonly found in ASSD and most connective 
tissue diseases-related ILD5,33, whereas a pattern of UIP is more frequently observed in patients with IPF and 
RA-ILD28. Because of that, it is possible that MUC5B rs35705950 may modulate phenotype differences amongst 
these conditions, suggesting that this genetic variant is not related to shared fibrotic mechanisms across diseases 
related to ILD, but is instead associated with an IPF and RA-ILD specific pathway. A potential bias may exist in 
our study regarding the fact that declarative data on the European ancestry were collected from patients and 
controls included.
In summary, our study does not support a role of MUC5B rs35705950 in ASSD pathogenesis. It also indicates 
that there are genetic differences between ILD associated with and that unrelated to ASSD.
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